openPR Logo
Press release

Huateng Pharma Develops Caronic Anhydride & Derivatives As Paxlovid Intermediates

Huateng Pharma Develops Caronic Anhydride & Derivatives As

On February 16, 2022, the data on Paxlovid previously published by Pfizer and submitted to the FDA were published in the New England Journal of Medicine (NEJM).

This NEJM article published viral load data that Paxlovid reduced viral load by 0.868 log10 compared to controls for 5 days of treatment, which equates to a remarkable 7.38-fold reduction in viral load. This pivotal study (NCT04960202) enrolled 2,246 patients with COVID-19, 1,120 received Paxlovid and 1,126 received placebo. Interim analysis showed that 28 days after receiving treatment, Paxlovid reduced the risk of hospitalization and death by 89.1% (p

Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, China
Manufacturing Base: Tongguan Kiln, Wangcheng district, Changsha, Hunan, China
Zip code: 410205
Telephone: +86 731 89916275
Fax: +86 0731-82251112-818

Huateng Pharma is a global provider in contract development and manufacturing for intermediates.  With our focus on operational excellence, and the integration of manufacturing operations with EHS, quality assurance, quality control, regulatory, supply chain management and project management, we can manufacture, scale-up and supply high-quality intermediates and APIs from our China facility.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Huateng Pharma Develops Caronic Anhydride & Derivatives As Paxlovid Intermediates here

News-ID: 2586559 • Views: 229

More Releases from Hunan Huateng Pharmaceutical Co. Ltd.

Huateng Pharma Develops Systemic Antiparasitic Agent Fluralaner
Fluralaner is a systemic insecticide and acaricide that can be administered orally or topically. Bravecto is the trade name. The U.S. Food and Drug Administration (FDA) approved it for flea treatment in dogs under the trade name Bravecto in May 2014 and for topical treatment in cats in November 2019. Fluralaner is a novel isooxazoline broad-spectrum insecticide that acts on γ-aminobutyric acid (GABA) receptors and has good activity against ticks, fleas,
Huateng Pharma Develops Intermediates of Carfilzomib For Multiple Myeloma
Carfilzomib, a proteasome inhibitor, is indicated for the treatment of patients with multiple myeloma. Multiple myeloma (multiple myeloma, MM) is a malignant tumor originating from the B cell lineage, characterized by the clonal proliferation of malignant plasma cells in the bone marrow microenvironment, causing fractures and bone marrow failure, and is the second most common blood system disease in the world Tumors cannot be cured by traditional chemotherapy regimens. Bortezomib is the
Huateng Pharma Develops Intermediates of Semaglutide For TD2
According to the latest IDF Diabetes map, the global prevalence of diabetes reached 10.5% in 2021, with 537 million adults living with diabetes. China has become a disaster zone for diabetes, with the largest number of adults with diabetes in the world. In the past 10 years (2011-2021), the number of people with diabetes in China increased from 90 million to 140 million, an increase of 56%. The total number
The Future of Treatment For Type 2 Diabetes
Although the treatment of type 2 diabetes (T2DM) has made impressive progress in the past few decades, researchers are constantly searching for new treatments. How to better control blood glucose and reduce diabetes-related complications has become a hot topic in the field of T2DM research. Previously, The Lancet Diabetes Endocrinology published an in-depth review detailing novel therapeutic targets for T2DM, mechanisms of drug action, and corresponding hypoglycemic efficacy. It involves innovation

All 5 Releases

More Releases for Paxlovid

Pediatric Clinical Trials Market Overview, Trends, Growth, Demand, Key Players A …
According to Future Market Insights, the global pediatric clinical trials Market Share is projected to grow steadily at a 5.3% value CAGR, during the forecast period 2022-2032. Earlier in 2021, this market was projected to have a global market valuation worth US$ 15 Billion and is expected to reach a sum of US$ 26.47 Billion by 2032. Due to unmet healthcare needs in the pediatric patient population, there is a considerable
COVID-19 Therapeutics Market Research Insight 2022| Industry Development - Growt …
InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global COVID-19 Therapeutics Market by (Product (Remdesivir, Casirivimab/imdevimab, Bamlanivimab and etesevimab, Sotrovimab, Molnupiravir, Other), Drug Class (Monoclonal Antibodies, Antiviral, Anticoagulant, Glucocorticoid, Nitric oxide, and Other Drug Class)) - Market Outlook and Industry Analysis 2030" According to company's newest research, the global COVID-19 Therapeutics Market is worth US$ 10.2 Billion in 2021 and is predicted to
Covid-19 Treatment Medicine Market Trends, Industry Size and Manufacturers Futur …
The Covid-19 Treatment Medicine research report is the professional report with the premium insights which includes the size of the business, the ongoing patterns, drivers, dangers, conceivable outcomes and primary segments. The Market Report predicts the future progress of the Covid-19 Treatment Medicine market based on accurate estimations. Furthermore, the report offers actionable insights into the future growth of the market based on inputs from industry experts to help readers
Huateng Pharma Supplies Ensitrelvir Intermeidates Against COVID-19
Ensitrelvir (code name S-217622, brand name Xocova), is a new inhibitor of the SARS-CoV-2 major protease (Mpro), also known as 3C-like protease, has been shown to reduce the viral load and help alleviate the severity of SARS-CoV-2 in infected hamsters. In cells, low nanomolar to sub-micromolar doses of Ensitrelvir suppress viral growth. In hamsters, oral treatment of Ensitrelvir showed excellent pharmacokinetic qualities and hastened recovery from acute SARS-CoV-2 infection. Ensitrelvir
Industry Overview of Antiviral Drugs Market: Report Based on Development, Scope, …
The global antiviral drugs market is anticipated to grow at a significant CAGR of 4.0% during the forecast period 2022-2028. The global antiviral drug market is being driven by an increase in viral diseases such as the Human Immunodeficiency Virus (HIV), influenza A and B, hepatitis B and C, herpes, chickenpox, and papilloma, among others. One of the most common viral infectious illnesses is HIV. According to World Health
Oral COVID-19 Antiviral Medicine Market to Witness Huge Growth by 2027
DeepResearchReports has uploaded a latest report on Oral COVID-19 Antiviral Medicine Industry from its research database. Oral COVID-19 Antiviral Medicine Market is segmented by Regions/Countries. All the key market aspects that influence the Oral COVID-19 Antiviral Medicine Market currently and will have an impact on it have been assessed and propounded in the Oral COVID-19 Antiviral Medicine Market research status and development trends reviewed in the new report. The